Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,Matthew Davids, MD, MMSc

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), particularly in optimizing treatment duration and sequencing to improve patient outcomes.

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP: 5.Future Directions and Research Priorities in BTKi Treatment Approaches

EP: 6.Latest Trends and Innovations in CLL and MCL Treatment

EP: 7.CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP: 8.Navigating CLL Treatment Choices

EP: 9.Therapy Sequencing in CLL

EP: 10.MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP: 11.MCL Therapy Selection and Sequencing

EP: 12.Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

Now Viewing

EP: 13.Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

Were there any particularly exciting updates or data presented at ASH 2024 that could influence how BTK inhibitors are used in clinical practice for CLL and MCL?